STATS Flashcards
1
Q
Appendicitis in Pregnancy
A
1:1500
2
Q
Vasectomy
A
1: 2000
3
Q
Female sterilisation
A
1: 200
hysteroscopic - 2: 1000
4
Q
Heterotopic pregnancy
A
1: 30000
8: 1000 with ART
5
Q
Maternal Cardiac arrest
A
1: 12500 / 1: 30000
6
Q
Coil Expulsion
A
1: 20
7
Q
Coil Perforation
A
1-2: 1000
Increased risk by 6-8 times if between 48 hours or 6 weeks following pregnancy
8
Q
Female condom failure
A
22%
Male 18%
9
Q
Rate of twin pregnancies
A
3%
Note maternal mortality is 2.5 higher than general population
10
Q
Turners Syndrome
A
1: 2500 - 1: 3000
11
Q
Stress Urinary Incontinence
A
1: 3
12
Q
Pelvic floor prolapse
A
1: 9
13
Q
Combined test detection rate
A
90%
14
Q
Reversion to breech following ECV
A
3%
15
Q
Risk of shoulder dystocia
A
<1% (0.58 - 0.7%)
If previous then x 10 higher
16
Q
Risk of shoulder dystocia after 1 previous
A
<1% (0.58 - 0.7%)
If previous then x 10 higher
17
Q
Risk of endometrial hyperplasia with granulosa cell tumour
A
40% risk of EH
10-15% risk of endometrial cancer
18
Q
Risk of endometrial cancer with granulosa cell tumour
A
40% risk of hyperplasia
10-15% risk of endometrial cancer
19
Q
Risk of uterine rupture
A
1: 200 - 0.5% or 0.2-0.7%
if labour augmentation risk 2-3x higher
20
Q
Risk of repeat LSCS with VBAC
A
1: 4
21
Q
Fetal laceration at LSCS
A
2%
22
Q
Risk of OASIS
A
2.9%
6.1% - Primip
1.7% - multip
Recurrence 5-7%
5% with VBAC
60-80% asymptomatic at 12 months
23
Q
Risk of OASIS in multip
A
2.9%
6.1% - Primip
1.7% - multip
Recurrence 5-7%
5% with VBAC
60-80% asymptomatic at 12 months
24
Q
Risk of OASIS in primp
A
2.9%
6.1% - Primip
1.7% - multip
Recurrence 5-7%
5% with VBAC
60-80% asymptomatic at 12 months
25
Risk of OASIS after previous
2.9%
6.1% - Primip
1.7% - multip
Recurrence 5-7%
5% with VBAC
60-80% asymptomatic at 12 months
26
Post-partum Psychosis
1-2: 1000
27
Post-partum psychosis in bipolar
1: 4
28
Risk of twins delivering before 37 weeks
60%
29
Risk of triplets delivering before 35
75%
30
Rate of MCDA
30% OF TWINS
31
Rate of MCMA
1% of twins
32
Uterine perforation in EVAC
1: 1000
33
VBAC success rate
72-75%
| Px VD 85-90%
34
Risk of repeat ectopic
18.5%
35
Mitochondrial disorders
1: 5000 - 1: 8000
36
GBS positive risk of neonatal transmission
1: 400 ( 2-3: 1000)
| If GBS positive previous pregnancy and not tested in current pregnancy risk is 1:800
37
Risk of cord prolapse
0.1 - 0.6%
38
Diabetes Insipidus
2-4 : 100, 000
39
Laproscopic abdominal cerclage risk of conversion to open
10%
| > 85% successful pregnancy rate
40
Primary herpes infection neonatal infection risk
41%
41
Recurrent Herpes risk of neonatal infection
0-3%
42
Placenta praevia after 1 LSCS
1 LSCS 1%
2 LSCS 1.7%
3 LSCS 2.8%
4-8 / 1000 - praevia / accreta
43
Placenta praevia after 2 LSCS
1 LSCS 1%
2 LSCS 1.7%
3 LSCS 2.8%
44
Placenta praevia after 3 LSCS
1 LSCS 1%
2 LSCS 1.7%
3 LSCS 2.8%
45
VERTEX
SUBOCIPITO-BREGMATIC 9.5cm
46
FACE
SUBMENTO-BREGMATIC 9.5cm
47
OP
OCCIPTIO-FRONTAL 11.5cm
48
BROW
MENTO-VERTICAL 13cm
49
Risk of chorioamnionitis following amniocentesis
1: 1000
Miscarriage risk 1%
50
Risk of miscarriage following amniocentesis
Miscarriage risk 1%
51
Complications in planned LSCS
16 : 100
24: 100 in LSCS performed in labour
33: LSCS at 9-10cm dilated
52
Complications in LSCS performed in labour
24: 100
33: LSCS at 9-10cm dilated
16: 100 in planned LSCS
53
Emergency hysterectomy in LSCS
7-8: 1000
| 11: 100 with placenta praevia
54
Bladder injury at LSCS
1: 1000
55
Ureteric injury at LSCS
1: 10000
56
Death at LSCS
1: 12,000
57
Risk of haemorrhage at LSCS
5: 1000
58
Risk of infection at LSCS
6: 100
59
Emergency hysterectomy with placenta praevia
11: 100
27: 100 if previous section
60
VTE in placenta praevia at LSCS
3: 100
61
Bladder injury / ureteric at LSCS in plaenta praevia
6: 100
62
Future placenta praevia
23: 1000
63
Massive obstetric haemorrhage with placenta praevia
21: 100
64
Very common
1: 1 - 1: 10 (family member)
65
Common
1:10 - 1: 100 ( person in street)
66
Uncommon
1: 100 - 1: 1000 ( person in village)
67
Rare
1: 1000 - 1: 10000 ( person in small town)
68
Very rare
< 1: 10,000 ( person in large town)
69
Risk of serious injury at diagnostic lap
2: 1000
15% of bowel injuries may not be noticed at time of procedure
70
Risk of adhesions under the umbilicus following low transverse incision
23%
| 50 - with midline
71
Risk of adhesions under the umbilicus following midline laparotomy
50%
| 23% with low transverse
72
Percentage of bowel injuries not recognised at time of laparosopy
15%
73
Percentage of women who could die during laparsocop
3-8: 100 000
74
Percentage of women under MTX for ectopic requiring surgery
10%
75
OASIS with vacuum
1-4: 100
1: 10 - vulval tear
8-12: 100 - forceps
1: 5 - vulval tear
76
OASIS with foceps
8-12: 100
1: 5 - vulval tear
1-4: 100 - vacuum
1: 10 - vulval tear
77
Cephalohaematoma
Bleed limited to periostium
Does not cross suture lines
1-12 : 100
78
Subgaleal haematoma
```
Most serious
Crosses suture lines
Between periostium and aponeurosis
Puffy eyelids
3-6 : 100
```
79
Common risks with 3/4th tear
faecal urgency 26: 100
Perineal pain 9: 100
Wound Infection 8: 100
80
Intrauterine adhesions following miscarriage
19% ( evac 16 - 18%)
81
Vaginal surgery for prolapse damage to bladder
2: 1000
82
Vaginal surgery for prolapse damage to bowel
5: 1000
83
Damage to bladder or ureter at TAH
7: 1000
Bowel 4: 10 000
84
TAH haemorrage
| TAH return to theatre
23: 1000
7: 1000
85
COHORT
Group sharing common characteristics
For PROGNOSIS study
Followed over time to see how many will develop the outcome
86
CROSS-SECTIONAL
Diagnostic tests
| Characteristics of a population / sample observed at a point in time
87
CASE-CONTROL
Studies association of disease compared with past exposure
88
Fetal genotyping for red cell antibodies
16/40 for all except k - 20 weeks
89
When to refer to FMU with antibody titres - D, C, K
D - > 4iu
C - > 7.5iu
K - Any level
90
TTTS affects ? of MC pregnancies
15%
91
Tx anaphylaxis
500mcg , 0.5ml of 1: 1000 adrenaline IM
92
Breech pregnancy rate
3=4%
93
Recurrence of breech in future pregnancy
10%
94
Spontaneously revert to cephalic after 36/40
3-7%
95
Infectious period of VZV
INCUBATION 1-3 Weeks, infectious 48 hours before rash and until lesions crusted over.
96
Prevelence of primary chicken pox in pregnancy
3: 1000
97
Chemotherapy in breast cancer
Anthracyclines - Doxorubicin , Epirubicin
98
Agents in breast cancer associated with gonadal toxicity
Alkylating agents - cyclophosphamide
99
VWD
```
Chromosome 12
Type 1+2 Autosomal dominant
Type 3 autosomal recessive
Associated with a prolonged APTT
vWF AND FACTOR VIII should be checked pre invasive procedure. VIII >50
secondary PPH 25%
```
100
encapsulated bacteria
neisseria meningitis, strep pneumoniae, h. influenzae B
101
Normal NT thickness
<3.5mm
102
High risk screening
1: 150
103
Antenatal appointments
Nullip 10
| Multip 7
104
PET RF
```
BMI > 30
FH PET
Px PIH / PET
PRIMIP
>10 YEARS SINCE LAST DELIVERY
AGE >40
MULTIPLE PREG
Pre-existing vascular disease / renal disease
```
105
Labour pains
T10 - L1 inferior hypogastric plexus
106
Placental abrution recurrence
4.4% - 1 preg
| 19 - 25% - 2 preg
107
Emergent bleed with placenta praevia
35 - 4.7%
36 - 15%
37 - 30%
38 - 59%
108
vasa praevia
1: 1200-5000
Fetal mortality 60%
A vessel running in the free placental membranes within 2cm of the cervix
109
VTE in pregnancy
1: 1000
Risk is 4-6 times greater in pregnancy
5 x greater risk post-natal than antenatal
110
Recurrent VTE in preg
2-11 %
111
Conditions requiring higher doses of LMWH
VTE and antithrombin deficiency
VTE associated with APS
VTE recurrently
112
Placenta acreta in placenta praevia with previous LSCS
1 LSCS - 11-14%
2 LSCS - 23-40%
UPTO 67 with >5
113
Risk of death - diagnostic lap
3-8 : 100, 000
